Buy & Sell Vertex Pharmaceuticals Incorporated (VRTX) – Vertex Pharmaceuticals Incorporated Price Today
Aura AI Summary
Key Stats
- $116.49BMarket Cap
- HealthSector
- -6.97%3M Drawdown
- $111.23BEnterprise Value
- -Dividend Yield
- 46% Buy | 54% SellTrading Activity
- 105 daysTypical Hold Time
Vertex Pharmaceuticals Incorporated (VRTX) is currently valued at a market capitalization of $116.49B, with an enterprise value of $111.23B. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $499.17, highlighting its annual price range. Over the past three months, Vertex Pharmaceuticals Incorporated has recorded a drawdown of -6.97%, reflecting recent price volatility. On average, investors hold Vertex Pharmaceuticals Incorporated for approximately 105 days, indicating typical investor behavior on the platform.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Most Recent News
Automated liquid handling systems market to reach $6.9B by 2035, growing at 9.8% CAGR driven by pharma and biotech demand.
The global automated liquid handling systems market was valued at $2.7 billion in 2025 and is projected to grow to $6.9 billion by 2035, with a compound annual growth rate (CAGR) of 9.8%. This growth is driven by increasing pharmaceutical and biotech...
Indian IT stocks drop up to 7% after Accenture cuts revenue forecast amid AI and economic worries
Shares of major Indian IT companies fell sharply, with Infosys down over 7% and Tata Consultancy Services dropping more than 5%, following Accenture's lowered revenue guidance for FY 2026. Accenture cited a $100 million impact from the Middle East an...
Sunway MCL and CSC Land top bid $581M for prime Singapore residential site amid strong property demand
Sunway MCL, led by Malaysian billionaire Jeffrey Cheah, and partner CSC Land Group placed the highest bid of S$751 million ($581 million) for a 99-year leasehold residential site at River Valley Green in Singapore. This bid is about 22% higher than a...